DE602004017290D1 - Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel - Google Patents

Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel

Info

Publication number
DE602004017290D1
DE602004017290D1 DE602004017290T DE602004017290T DE602004017290D1 DE 602004017290 D1 DE602004017290 D1 DE 602004017290D1 DE 602004017290 T DE602004017290 T DE 602004017290T DE 602004017290 T DE602004017290 T DE 602004017290T DE 602004017290 D1 DE602004017290 D1 DE 602004017290D1
Authority
DE
Germany
Prior art keywords
agents
contrast
conjugates
including carrier
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017290T
Other languages
English (en)
Inventor
John Rodney Woodrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Biopharma DK AS
Upperton Ltd
Original Assignee
Upperton Ltd
Novozymes Biopharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0303532A external-priority patent/GB0303532D0/en
Priority claimed from GB0303533A external-priority patent/GB0303533D0/en
Application filed by Upperton Ltd, Novozymes Biopharma UK Ltd filed Critical Upperton Ltd
Publication of DE602004017290D1 publication Critical patent/DE602004017290D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A61K49/1869—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid coated or functionalised with a protein being an albumin, e.g. HSA, BSA, ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1878—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating
    • A61K49/1881—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles the nanoparticle having a magnetically inert core and a (super)(para)magnetic coating wherein the coating consists of chelates, i.e. chelating group complexing a (super)(para)magnetic ion, bound to the surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE602004017290T 2003-02-17 2004-02-17 Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel Expired - Lifetime DE602004017290D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0303532A GB0303532D0 (en) 2003-02-17 2003-02-17 Particles for the delivery of agents to the body
GB0303533A GB0303533D0 (en) 2003-02-17 2003-02-17 Delivery of agents to the body
PCT/GB2004/000582 WO2004071536A1 (en) 2003-02-17 2004-02-17 Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent

Publications (1)

Publication Number Publication Date
DE602004017290D1 true DE602004017290D1 (de) 2008-12-04

Family

ID=32870957

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017290T Expired - Lifetime DE602004017290D1 (de) 2003-02-17 2004-02-17 Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel

Country Status (10)

Country Link
US (2) US20060171892A1 (de)
EP (1) EP1605979B1 (de)
JP (1) JP2006518727A (de)
KR (1) KR20050121673A (de)
AT (1) ATE411819T1 (de)
AU (1) AU2004212263B2 (de)
CA (1) CA2516409A1 (de)
DE (1) DE602004017290D1 (de)
ES (1) ES2316961T3 (de)
WO (1) WO2004071536A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014728A1 (de) 2005-01-13 2009-01-14 Cinvention Ag Verbundstoffmaterialbeschichtungen
US20080206152A1 (en) * 2005-06-07 2008-08-28 Koninklijke Philips Electronics, N.V. In Vivo Expression Profiling
US9623129B2 (en) * 2005-09-26 2017-04-18 Snip Holdings, Inc. Methods and therapies for treating inflammatory conditions with exposed collagen
WO2007071068A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
FR2909881A1 (fr) * 2006-12-14 2008-06-20 Inst Nat Sante Rech Med Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation
JP2010535484A (ja) 2007-08-08 2010-11-25 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ トランスフェリン変異体と複合体
KR101050401B1 (ko) * 2008-05-09 2011-07-19 경북대학교 산학협력단 이중 방식 ｐｅｔ／ｍｒ 조영제
EP2396347B1 (de) 2009-02-11 2017-04-12 Albumedix A/S Varianten und konjugate von albumin
KR20120018762A (ko) * 2009-04-08 2012-03-05 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 제어된 혈청 약동학적 특성을 갖는 인간 단백질 스캐폴드
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
EP2635598A1 (de) 2010-11-01 2013-09-11 Novozymes Biopharma DK A/S Albuminvarianten
EP2694117A4 (de) * 2011-04-06 2014-06-11 Cedars Sinai Medical Center Bildgebungs-nanokonjugate auf basis von polymaleinsäure
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
EP2956002B1 (de) 2013-02-16 2017-09-06 Albumedix A/S Pharmakokinetisches tiermodell
CN104274827B (zh) 2013-07-01 2020-07-14 上海贺普药业股份有限公司 贺普拉肽的制剂
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
EP3755381A1 (de) 2018-02-21 2020-12-30 Sorbonne Université Auf entzündungen gerichtete, optische kontrastmittel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1177381B (it) * 1984-12-11 1987-08-26 Baldacci Lab Spa Metodo per la preparazione di coniugati della adenina-9-beta-d-arabino furano-side 5' monofosfato con albumina umana lattosaminata, coniugati risultanti e relative composizioi terapeuticamente attive
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0654973A4 (de) * 1992-07-21 1995-08-09 Gen Hospital Corp Anordnung zur abgabe von medikamenten an das lymphgewebe.
US6009342A (en) * 1997-02-28 1999-12-28 The Regents Of The University Of California Imaging method for the grading of tumors
US5929044A (en) * 1997-08-14 1999-07-27 Cornell Research Foundation Protein solder composition and method of use
IT1318485B1 (it) * 2000-04-21 2003-08-25 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari

Also Published As

Publication number Publication date
AU2004212263A2 (en) 2004-08-26
JP2006518727A (ja) 2006-08-17
ES2316961T3 (es) 2009-04-16
ATE411819T1 (de) 2008-11-15
WO2004071536A1 (en) 2004-08-26
EP1605979A1 (de) 2005-12-21
AU2004212263B2 (en) 2009-12-03
US20110142762A1 (en) 2011-06-16
EP1605979B1 (de) 2008-10-22
US20060171892A1 (en) 2006-08-03
CA2516409A1 (en) 2004-08-26
KR20050121673A (ko) 2005-12-27
AU2004212263A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
DE602004017290D1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
MXPA05007439A (es) Compuestos de peptido liberador de gastrina mejorados.
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
ATE527552T1 (de) Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe
WO2005061009A3 (en) Microparticles for microarterial imaging and radiotherapy
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
SG152254A1 (en) Contrast agents for myocardial perfusion imaging
WO2007117467B1 (en) Use of tm-601 for the diagnosis and treatment of tumors
ATE530168T1 (de) Magnetische nanoteilchen-zusammensetzungen und ihre verwendungen
WO2006088476A3 (en) Carboranylporphyrins and uses thereof
EP2099304A4 (de) Carboranylporphyrine und ihre verwendungen
Hagtvet et al. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts
Bryan et al. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy
Mirjolet et al. Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model
ATE434445T1 (de) Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper
EP1830879A4 (de) Mrt-geführte photodynamische therapie gegen krebs
HK1109039A1 (en) Carboranylporphyrins and uses thereof
EP1749026A4 (de) Markierte adrenomedullinderivate und deren verwendung zur bilddarstellung und therapie
HK1068251A1 (en) Aminoderivatives of biotin and their conjugates with macrocyclic chelating agents
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
ATE365170T1 (de) Komplexverbindungen aus paramagnetischem metall und phthalocyanin und kontrastmittel, bei dem diese verbindungen verwendet werden
Chang et al. External beam radiotherapy synergizes 188Re-liposome against human esophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics
TW200744647A (en) Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents
MXPA05010804A (es) Torio 227 para uso en radioterapia de enfermedades del tejido blando.
US20150050213A1 (en) Compositions and methods for imaging inflammation of traumatic brain injury

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UPPERTON LTD., WEST BRIDGFORD, NOTTINGHAM, GB

Owner name: NOVOZYMES BIOPHARMA DK A/S, BAGSVAERD, DK